Neither Breztri nor Trelegy is clearly better than the other. Both are triple-combination COPD inhalers that deliver the same three types of medication: an inhaled corticosteroid to reduce inflammation, a long-acting muscarinic antagonist to open the airways, and a long-acting beta-agonist to keep them open. They use different specific drugs to accomplish this, and they differ in dosing frequency, inhaler design, and the strength of evidence behind certain outcomes. The best choice depends on your individual needs, how well you can use each device, and what your insurance covers.
What Each Inhaler Contains
Breztri Aerosphere combines budesonide (the steroid), glycopyrrolate (the airway opener that blocks a nerve signal), and formoterol (the airway opener that relaxes muscle). You take two puffs twice a day from a pressurized metered-dose inhaler, the classic “puffer” style device. That’s four total inhalations per day.
Trelegy Ellipta combines fluticasone furoate, umeclidinium, and vilanterol in the same three drug classes. You take one inhalation once a day from a dry powder inhaler. The difference in dosing frequency is one of the most practical distinctions between the two.
How the Inhaler Devices Differ
Breztri uses a pressurized metered-dose inhaler (MDI). A propellant pushes the medication out as a fine mist when you press the canister. The catch is timing: you need to coordinate pressing down on the canister with breathing in. If your timing is off, less medication reaches your lungs. A spacer can help, but it adds an extra piece of equipment.
Trelegy uses a dry powder inhaler (DPI). There’s no propellant. Instead, you take a quick, deep breath to pull the powdered medication into your lungs. This eliminates the coordination problem, but it requires enough lung power to generate a strong inhalation. For people with very severe COPD who struggle to breathe in forcefully, this can be a limitation.
In studies comparing the Ellipta device to other inhaler types, patients who expressed a preference favored the Ellipta by roughly three to one for number of steps, time to use, and ease of use. That preference hasn’t been tested head-to-head against the Breztri Aerosphere specifically, but the simplicity of one inhalation once daily is a genuine advantage for people who find inhaler routines difficult to maintain.
Reducing Flare-Ups and Improving Breathing
Both inhalers were proven effective in large clinical trials. Breztri was studied in the ETHOS trial, and Trelegy was studied in the IMPACT trial. Each showed that triple therapy reduced moderate-to-severe COPD flare-ups compared to dual therapy (two-drug combinations). No large head-to-head trial has directly compared the two triple combinations against each other, so claims that one reduces exacerbations more than the other rely on indirect comparisons across different study populations.
A meta-analysis comparing the available triple therapies found both effective at improving lung function and reducing flare-ups. The improvements in airflow measured in clinical trials were broadly similar. In practice, your response to either inhaler will depend on factors like your baseline lung function, how consistently you use the device, and whether the specific steroid component agrees with your body.
Mortality Evidence
This is one area where Trelegy has stronger published data. The IMPACT trial found that Trelegy reduced the risk of death by 28% compared to a two-drug combination that left out the steroid component. That was a statistically significant result, and it marked the first time a triple inhaler therapy demonstrated a mortality benefit in a prospective clinical trial.
The ETHOS trial for Breztri also showed a trend toward reduced mortality, but the results were not as robust. This doesn’t necessarily mean Breztri is less effective at preventing death. It may reflect differences in how the trials were designed, how long they ran, and which patients enrolled. Still, if mortality data specifically matters to you or your prescriber, Trelegy currently has the stronger evidence on that front.
Pneumonia and Side Effect Risk
Both inhalers contain a steroid component, and all inhaled steroids carry some risk of pneumonia. A large real-world cohort study published in The BMJ compared the two triple therapies directly and found the risk of hospitalization for pneumonia was essentially identical between Breztri and Trelegy users. The hazard ratio was 1.00, meaning no detectable difference. The overall rate of pneumonia hospitalization across both groups was about 105 per 1,000 person-years of use.
Other steroid-related side effects like oral thrush, bone thinning, and adrenal suppression are possible with both inhalers. These risks are generally tied to the steroid dose and duration of use rather than to which specific product you take. Rinsing your mouth after each use helps reduce the risk of thrush regardless of which inhaler you’re on.
Once Daily vs. Twice Daily
Trelegy’s once-daily dosing is simpler. You open the inhaler, breathe in, and you’re done for 24 hours. Breztri requires two puffs in the morning and two puffs in the evening. For someone managing multiple medications, that difference in routine complexity can affect whether doses get missed. Missed doses mean less medication in your lungs and potentially more flare-ups.
On the other hand, twice-daily dosing with Breztri means the medication is refreshed every 12 hours. Some people feel this provides more consistent symptom control throughout the day, particularly if they notice their symptoms returning in the evening or early morning. This is a subjective experience and varies from person to person.
Cost Considerations
The retail price of Trelegy is approximately $698 for a 30-day supply. Breztri falls in a similar range, though exact pricing varies by pharmacy. Both are brand-name medications with no generic versions available, so without insurance they are expensive.
Your actual out-of-pocket cost depends heavily on your insurance plan’s formulary. Some plans place one on a preferred tier and the other on a higher-cost tier, which can make the price difference significant. Both manufacturers offer savings programs that may reduce your copay. Medicare Part D and Medicare Advantage plans can cover either, but prior authorization is commonly required. If your plan covers one but not the other, that alone may settle the decision.
How to Choose Between Them
If you value simplicity and have the lung strength for a deep, quick inhalation, Trelegy’s once-daily dry powder inhaler is the more convenient option with strong patient preference data behind its device. If you have trouble generating a forceful breath, or if you’re already comfortable with the press-and-breathe technique of a metered-dose inhaler, Breztri may be the better fit.
If published mortality data weighs heavily in your decision, Trelegy has the edge based on the IMPACT trial. If your insurance formulary strongly favors one over the other, cost may be the deciding factor. Both deliver the same category of treatment, both reduce flare-ups effectively, and both carry similar safety profiles in real-world use. The “better” inhaler is the one you’ll use correctly and consistently.